Citation

Stene LE, Dyb G, Tverdal A, Jacobsen GW, Schei B. BMJ Open 2012; 2(2): e000614.

Affiliation

Department of Public Health and General Practice, Norwegian University of Science and Technology, Trondheim, Norway.

Copyright

(Copyright © 2012, BMJ Publishing Group)

DOI

10.1136/bmjopen-2011-000614

PMID

22492384

PMCID

PMC3323816

Abstract

OBJECTIVES: To investigate the prescription of potentially addictive drugs, including analgesics and central nervous system depressants, to women who had experienced intimate partner violence (IPV). DESIGN: Prospective population-based cohort study. SETTING: Information about IPV from the Oslo Health Study 2000/2001 was linked with prescription data from the Norwegian Prescription Database from 1 January 2004 through 31 December 2009. PARTICIPANTS: The study included 6081 women aged 30-60 years. MAIN OUTCOME MEASURES: Prescription rate ratios (RRs) for potentially addictive drugs derived from negative binomial models, adjusted for age, education, paid employment, marital status, chronic musculoskeletal pain, mental distress and sleep problems. RESULTS: Altogether 819 (13.5%) of 6081 women reported ever experiencing IPV: 454 (7.5%) comprised physical and/or sexual IPV and 365 (6.0%) psychological IPV alone. Prescription rates for potentially addictive drugs were clearly higher among women who had experienced IPV: crude RRs were 3.57 (95% CI 2.89 to 4.40) for physical/sexual IPV and 2.13 (95% CI 1.69 to 2.69) for psychological IPV alone. After full adjustment RRs were 1.83 (1.50 to 2.22) for physical/sexual IPV, and 1.97 (1.59 to 2.45) for psychological IPV alone. Prescription rates were increased both for potentially addictive analgesics and central nervous system depressants. Furthermore, women who reported IPV were more likely to receive potentially addictive drugs from multiple physicians. CONCLUSIONS: Women who had experienced IPV, including psychological violence alone, more often received prescriptions for potentially addictive drugs. Researchers and clinicians should address the possible adverse health and psychosocial impact of such prescription and focus on developing evidence-based healthcare for women who have experienced IPV.

Language: en